Please assess the completion status of the following clinical trial:

Trial Title: NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histological diagnosis of hepatocellular carcinoma, bladder cancer, breast cancer, non-small lung cancer (NSCLC), melanoma, sarcoma, prostate cancer, esophageal cancer, or ovarian cancer, independent of NY-ESO-1 expression in a tumor biopsy.~   or~   Histological diagnosis of other types of cancers, provided NY-ESO-1 or LAGE-1 expression can be shown in a tumor biopsy.~2. At least 4 weeks since surgery prior to first dosing of study agent.~3. Laboratory values within the following limits:~   * Hemoglobin ≥ 11.0 g/dL~  * Neutrophil count ≥ 1.5 x l0\^9/L~  * Lymphocyte count ≥ lower limit of institutional normal~  * Platelet count ≥ 80 x l0\^9/L~  * Serum creatinine ≤ 2.0 mg/dL~  * Serum bilirubin ≤ 2 x upper limit of institutional normal~  * AST/ALT ≤ 2 x upper limit of institutional normal~4. Patients must have a Karnofsky performance status of ≥70%.~5. Life expectancy ≥ 6 months.~6. Age ≥ 18 years.~7. Able and willing to give witnessed, written informed consent for participation in the trial.~Exclusion Criteria:~1. Clinically significant heart disease (i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias).~2. Other serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders.~3. Previous bone marrow or stem cell transplant.~4. History of immunodeficiency disease or autoimmune disease except vitiligo.~5. Metastatic disease to the central nervous system, unless treated and stable.~6. Other malignancy within 3 years prior to entry into the study, except for treated early-stage melanoma or non-melanoma skin cancer, or cervical carcinoma in situ.~7. Known HIV, Hepatitis B or Hepatitis C positivity.~8. Chemotherapy, radiation therapy or immunotherapy within 4 weeks prior to first dose of study agent (6 weeks for nitrosoureas).~9. Concomitant treatment with steroids. Topical or inhalational steroids are permitted.~10. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dose of study agent.~11. Pregnancy or lactation.~12. Women of childbearing potential not using a medically acceptable means of contraception.~13. Psychiatric or addictive disorders that may compromise the ability to give informed consent.~14. Lack of availability of the patient for immunological and clinical follow-up assessment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A; 100 μg NY-ESO-1 protein co-mixed with CpG 7909 and Montanide ISA-51 VG (Type: EXPERIMENTAL): 100 μg NY-ESO-1 protein co-mixed with 2.5 mg CpG 7909 and 1.25 mL Montanide ISA-51 VG. The vaccine was administered subcutaneously every 3 weeks for a total of 4 doses (study weeks 1, 4, 7 and 10).
- Arm B; 400 μg NY-ESO-1 protein co-mixed with CpG 7909 and Montanide ISA-51 VG (Type: EXPERIMENTAL): 400 μg NY-ESO-1 protein co-mixed with 2.5 mg CpG 7909 and 1.25 mL Montanide ISA-51 VG. The vaccine was administered subcutaneously every 3 weeks for a total of 4 doses (study weeks 1, 4, 7 and 10).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete